Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 4/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063384 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3KLK7 | |
| SCHEMBL12531098 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3KLK7 | |
| SCHEMBL6491278 | 0.82 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3KLK7 | |
| SCHEMBL842624 | 0.81 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3KLK7 | |
| SCHEMBL13864152 | 0.81 | CHRM2 (0.40) | NR1H2CHRM2CHRM1CHRM3KLK7 | |
| SCHEMBL29997836 | 0.80 | KLK7 (0.50) | NR1H2KLK7 | |
| SCHEMBL13613731 | 0.80 | TOP2A (0.34) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL13613732 | 0.80 | TOP2A (0.34) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL17169858 | 0.80 | KLK7 (0.50) | NR1H2KLK7 | |
| SCHEMBL26045071 | 0.80 | TOP2A (0.34) | NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1314041-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | Annovis, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | ANNOVIS, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002018941-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | ANNOVIS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0809624-B1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | BEARSDEN BIO INC (US) | 2001-08-29 | — | — | EP | disclosed |
| US-5731348-A | NERVOUS SYSTEM DISORDERS | BEARSDEN BIO, INC. (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0809624-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | Bearsden Bio, Inc. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025387-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | SYMPHONY PHARMACEUTICALS, INC. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | SLC18A2, SLC1A2, SLC1A1 | NR1H2 1080/4885CHRM2 449/4885CHRM1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.